Profile data is unavailable for this security.
About the company
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.
- Revenue in CNY (TTM)1.62bn
- Net income in CNY-1.93bn
- Incorporated2012
- Employees2.53k
- LocationShanghai Junshi Biosciences Co Ltd16F, Building 7, No. 6, Lane 100Pingjiaqiao Road, Pudong New AreaSHANGHAI 201203ChinaCHN
- Phone+86 2 161058800
- Fax+86 2 161757377
- Websitehttps://www.junshipharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Joincare Pharmaceutical Group Ind. Co. | 16.16bn | 1.40bn | 18.12bn | 14.37k | 12.68 | 1.27 | -- | 1.12 | 0.7626 | 0.7626 | 8.76 | 7.64 | 0.4444 | 2.29 | 5.29 | 1,125,043.00 | 8.03 | 8.46 | 16.91 | 18.84 | 61.38 | 62.72 | 18.07 | 17.00 | 1.89 | -- | 0.2222 | 28.86 | -2.90 | 8.24 | -3.99 | 15.58 | 11.53 | 2.38 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.77bn | -408.93m | 20.79bn | 1.45k | -- | 3.43 | -- | 5.51 | -0.3139 | -0.3139 | 2.38 | 3.76 | 0.3611 | 0.476 | 3.69 | 2,598,424.00 | -3.92 | 8.97 | -5.65 | 13.15 | 41.80 | 45.59 | -10.85 | 20.12 | 1.19 | -3.44 | 0.3076 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Shanghai Junshi Biosciences Co Ltd | 1.62bn | -1.93bn | 20.84bn | 2.53k | -- | 3.72 | -- | 12.87 | -1.96 | -1.96 | 1.64 | 6.58 | 0.1422 | 0.8649 | 3.45 | 630,414.10 | -18.42 | -18.87 | -23.01 | -23.11 | 67.77 | 69.13 | -129.54 | -88.41 | 1.87 | -36.65 | 0.2801 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Tasly Pharmaceutical Group Co Ltd | 8.65bn | 1.03bn | 21.09bn | 9.22k | 20.66 | 1.68 | -- | 2.44 | 0.6833 | 0.6833 | 5.77 | 8.39 | 0.4973 | 1.68 | 10.87 | 938,279.60 | 5.65 | 5.47 | 6.96 | 7.25 | 65.99 | 48.42 | 11.36 | 8.94 | 2.40 | 4.60 | 0.2259 | 50.99 | 0.4236 | -13.57 | 505.34 | -7.07 | -3.03 | 1.92 |
| China Resources Dubl-Crne Phrmctl Co Ltd | 10.92bn | 1.60bn | 21.73bn | 12.27k | 13.39 | 2.16 | -- | 1.99 | 1.56 | 1.56 | 10.65 | 9.67 | 0.6991 | 2.82 | 5.58 | 889,809.70 | 10.21 | 8.40 | 14.77 | 11.08 | 55.29 | 58.19 | 14.60 | 11.98 | 1.14 | -- | 0.0247 | 35.91 | 6.20 | 4.44 | 12.96 | 6.60 | 21.46 | -1.63 |
| Hubei Jumpcan Pharmaceutical Co Ltd | 9.06bn | 2.82bn | 22.60bn | 5.23k | 7.98 | 1.67 | -- | 2.49 | 3.07 | 3.07 | 9.85 | 14.65 | 0.5262 | 3.09 | 4.60 | 1,732,306.00 | 16.41 | 16.23 | 21.92 | 20.88 | 79.06 | 82.64 | 31.20 | 24.42 | 3.13 | -- | 0.116 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Gan & Lee Pharmaceuticals | 2.69bn | 504.82m | 23.46bn | 4.48k | 44.56 | 2.14 | -- | 8.71 | 0.8759 | 0.8759 | 4.65 | 18.26 | 0.2375 | 0.8825 | 8.31 | 600,884.60 | 4.45 | 8.30 | 4.78 | 8.83 | 72.15 | 85.39 | 18.75 | 26.44 | 7.05 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.14bn | 1.01bn | 23.47bn | 8.22k | 22.87 | 2.67 | -- | 2.57 | 0.6995 | 0.6995 | 6.32 | 6.00 | 0.4681 | 1.09 | 3.23 | 1,112,139.00 | 5.16 | 5.67 | 7.35 | 8.07 | 60.27 | 60.52 | 11.03 | 11.61 | 0.8547 | 5.52 | 0.4506 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Kangmei Pharmaceutical Co Ltd | 4.97bn | 244.14m | 23.98bn | 4.41k | 97.80 | 3.40 | -- | 4.82 | 0.0177 | 0.0177 | 0.3596 | 0.5095 | 0.3447 | 1.39 | 2.50 | 1,127,547.00 | 1.71 | -17.60 | 2.59 | -32.24 | 21.52 | -72.78 | 4.96 | -101.19 | 0.8735 | -- | 0.1544 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Xiamen Amoytop Biotech Co Ltd | 2.39bn | 657.61m | 24.84bn | 1.96k | 37.77 | 12.33 | -- | 10.41 | 1.62 | 1.62 | 5.87 | 4.95 | 1.12 | 0.8751 | 5.89 | 1,217,627.00 | 30.81 | 17.96 | 35.47 | 21.02 | 92.97 | 90.48 | 27.55 | 19.17 | 3.34 | -- | 0.005 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
Data as of Sep 13 2024. Currency figures normalised to Shanghai Junshi Biosciences Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
13.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 41.63m | 6.21% |
| UBS Asset Management Switzerland AGas of 02 Jun 2023 | 10.31m | 1.54% |
| China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 8.31m | 1.24% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 6.14m | 0.92% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 4.96m | 0.74% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 4.91m | 0.73% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 4.61m | 0.69% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 4.34m | 0.65% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 3.51m | 0.52% |
| Tian Hong Asset Management Co., Ltd.as of 31 Dec 2023 | 3.00m | 0.45% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
